Passing Through the 20's, page-135

hopefully the opposite is true, if the early onset is the only period of effective outcome then it limits how well the treatment works and confines its use or when it can be used .....dopa doesnt chelate the way it is interpreted in some studies cos if it did then (likely) the alpha-synuclein protein would not have any advantage and constantly chelate new events and plaques would be limited to where the patient only has Parkinsonism

the patients who have a matured PD are just as good for the trial as they are less likely to recede the damage and more likely to struggle with any other form of therapy whereas early stage can or may show relief from topical treatments without receiving longterm benefit from those treatments. so, in that respect the longer term PD patients give a better insight into the effectiveness of NTcell